ReSurfX News

Introducing a powerful functional module SyRTOP to predict triggers and outcomes from the response of a system ('systems response') to our outcomes intelligence SaaS  product ReSurfX::vysen. These solutions are both artificial intelligence and expert enablers (where human intelligence is paramount). We have released information on how our powerful and novel 'data-source agnostic' machine learning approach 'Adaptive Hypersurface Technology' (AHT) is one of the most powerful solution when many combinations of inputs can lead to the same outcome. Variety of data sources are becoming available as is the ease to incorporate these into cause and outcomes determination workflows including in our target sectors Pharma, biotech and healthcare. We have now introduced a powerful new solution (SyRTOP) as a functional module to ReSurfX::vysen to gain insights on the causes and effects (and side-effects) of actions/treatments to alter them effectively (e.g., in patient outcomes, clinical trials, high cost treatments). Learn more about this solution here using a drug response case study - ReSurfX::vysen Yields Remarkably Accurate and Actionable Insights Using System Response to Triggers – A Drug Response Study. We also demonstrate that the solution we offer is far more accurate than widely used public domain and and commercial product solutions (that were among the best of available solutions). During our efforts found that 'current Knowledge Repositories (backend databases) have more than 30% errors', indicating a cause why even the most powerful infrastructure and solutions often don't live up to their hype.

Together with this module we also incorporated a continually increasing Knowledge Repository into ReSurfX::vysen, and Big Data solutions to help our customers make accurate knowledge sources even from their proprietary data.

While drug response is used as an example here, the value of SyRTOP solves various needs says Suresh Gopalan, our CEO and Founder - just in our initial target sectors applications include predicting patient outcomes, knowing unexpected outcomes, monitoring deviations from predicted behavior in clinical trials. He goes on to add that we are proud of our awesome team to innovate and incorporate another 'best in class' solution into ReSurfX::vysen enterprise SaaS product.

Releasing powerful and secure REST APIs and SDKs to our outcomes intelligence product enterprise SaaS product ReSurfX::vysen. A popular request from our customers to whom we are building end-to-end enterprise solutions for vertical integration and use, is ease of integration. We are proud of our leadership and technical teams for thoughtful and clean development of these additional functionalities says our Founder and CEO - Suresh Gopalan. This addition with our focus on end-to-end and 'best in class' applications that are continually added to our offerings help many classes of ongoing and upcoming data-intensive initiatives for and with our customers have significant impact on their ROI as captured in the simple pictorial below.

Key considerations in our product design strategy, besides smooth user interactions including in these APIs with well defined end-points and SDK wrappers that combine them as functional modules in addition through our interfaces (UI) in the web application. An example is the remark from a customer that "this is a remarkably smooth UI for a heavy grade application product of this nature".

We release a blog by Suresh Gopalan (our CEO and Founder) highlighting how we use 'combinatorics' and 'dimensionality' in solutions ReSurfX offer leveraging our novel machine learning solution 'Adaptive Hypersurface Technology' AHT. Typically both these aspects are considered problems including through the terms 'Curse of Dimensionality' and 'Combinatorial Explosion' in the use of Big Data. Some of our customers who personally have attempted to solve these problems or have tried other solutions share that they were stumped by these problems. Read more in our vysdom blog series 'Overcoming the Curse of Dimensionality with Combinatorics'.

ReSurfX, recently recognized as '20 Most Promising Data Analytics Vendors' by CIOReview is happy to announce accessibility of our SaaS product vysen (THE MOST ACCURATE IN THE MARKET) to more class of customers by pricing based on volume usage. Now we have expanded the access beyond the previous target of enterprise customers alone. Our value add is in line with many other accolades based on what we bring to the market and customers - including as an 'emerging company defining the next generation of personalized medicine platforms and technologies'.

ReSurfX has been recognized the "20 Most Promising Data Analytics Solutions Providers - 2017" by CIOReview magazine. We consider this a great honor that our creativity, value to market and customer centricity is recognized yet another time.

The list of 20 Companies can be seen here: //

The profile of our company has been published in online format online format and magazine format .

Click to view a local copy of the article here.

Another patent issued to ReSurfX in Israel. This is the 10th issued patent of ReSurfX, and expands the geographical scope of already very strong IP and patent portfolio of ReSurfX. The patent relates to parts of core technology invented by Suresh Gopalan, our CEO and Founder.

ReSurfX is proud to release our new version of our SaaS product ReSurfX::vysen 2.0 & a 30-day free trial version.

    This version features an awesome UI/UX tailored with modern features characteristic of smartphone generation not typically found in heavy duty analytics products. vysen 2.0 features great infrastructure built by experts with extreme security, scalability and customer enterprise integration perspective. The product is capable of repository scale processing and packs in the signature accuracy and innovation power, leveraging our novel 'Adaptive Hypersurface Technology' (AHT).

We are proud to welcome Dr. Fred Ausubel (Professor of Genetics, Harvard Medical School) an accomplished pioneer to our Board of Advisors effective February, 2015. We look forward to working with Dr. Ausubel to make faster progress towards our goals of enabling better data-based decisions and outcomes in life science and healthcare space, through improved accuracy and novel insights.

ReSurfX is proud to announce an agreement with a leading healthcare system to provide our solutions to a variety of problems. We believe this agreement will bring novel cost saving products and solutions for personalized and evidence based medicine to the healthcare marketplace with additional advantages and recognition to early adopters. We are also targeting to help research units make novel discoveries more effectively using our solutions.

Releasing our first web application product ReSurfX::vysen showcasing our novel 'Adaptive Hypersurface Technology' as a prelude to enterprise grade integrative analytics platform enabling better decisions and outcomes. This initial beta product is targeted towards data from a single gene expression technology.

1 2 3